ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Up 305.8% in December

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 41,800 shares, a growth of 305.8% from the December 15th total of 10,300 shares. Based on an average daily trading volume, of 12,800 shares, the days-to-cover ratio is presently 3.3 days.

Hedge Funds Weigh In On ProShares UltraShort Nasdaq Biotechnology

A hedge fund recently bought a new stake in ProShares UltraShort Nasdaq Biotechnology stock. Jane Street Group LLC acquired a new stake in shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 10,520 shares of the company’s stock, valued at approximately $158,000. Jane Street Group LLC owned 4.78% of ProShares UltraShort Nasdaq Biotechnology as of its most recent SEC filing.

ProShares UltraShort Nasdaq Biotechnology Trading Down 0.2 %

Shares of ProShares UltraShort Nasdaq Biotechnology stock traded down $0.05 on Tuesday, hitting $18.34. 4,834 shares of the company traded hands, compared to its average volume of 5,733. ProShares UltraShort Nasdaq Biotechnology has a 52 week low of $14.05 and a 52 week high of $21.10. The business has a 50-day simple moving average of $16.88 and a 200 day simple moving average of $15.81.

ProShares UltraShort Nasdaq Biotechnology Increases Dividend

The company also recently announced a dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 23rd were given a dividend of $0.2064 per share. This is an increase from ProShares UltraShort Nasdaq Biotechnology’s previous dividend of $0.15. The ex-dividend date of this dividend was Monday, December 23rd.

About ProShares UltraShort Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.